Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON45280
NL-OMON45280
Completed
Phase 2

Pilot Randomized-controlled phase-IIa trial on the prevention of comorbid Depression and Obesity in Attention-deficit / Hyperactivity disorder <br> - PROUD

Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt, Goethe Universität0 sites55 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsADHDattention deficit hyperactivity disorder10009841

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
ADHD
Sponsor
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt, Goethe Universität
Enrollment
55
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt, Goethe Universität

Eligibility Criteria

Inclusion Criteria

  • •\- All subjects must meet DSM\-5 criteria for a lifetime history of childhood onset ADHD (DSM\-5 314\.00, 314\.01\) as well as current ADHD criteria
  • •\- Age: 14\-30 years old.
  • •\- Stable TAU comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of BLT or AEI).

Exclusion Criteria

  • •\- Any severe medical or neurological condition interfering with interventions.
  • •\- Any severe medical or neurological condition not allowing BLT or AEI.
  • •\- Use of antipsychotic or anti\-epileptic medication, photos\-sensitising medication (e.g., Lithium, St. John's Wort)
  • •\- Substance use disorder (DSM\-5\) or dependency (DSM\-5\)
  • •\- History of epilepsy
  • •\- Acute suicidal ideation
  • •\- Pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A trial examining the effects of alteplase in patients with severe respiratory failure.
EUCTR2010-024377-40-ATMedizinische Universität Wien, UniKlinik für Klinische Pharmakologie
Active, not recruiting
Phase 1
Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM).EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSISMedDRA version: 21.0Level: PTClassification code 10049459Term: LymphangioleiomyomatosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2020-000702-29-ESIDIBELL (Institut d’Investigació Biomédica de Bellvitge)62
Not yet recruiting
Not Applicable
A short-term ketogenic diet combined with 24-hour fasting and chemoprotection for patients with acute myeloid leukaemia
ACTRN12620000850976epean Blue Mountains Local Health District134
Active, not recruiting
Not Applicable
/ASubjects affected by non-segmental vitiligoMedDRA version: 14.1Level: PTClassification code 10062080Term: Pigmentation disorderSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2011-000169-10-ITCLINUVEL PHARMACUETICALS LTD.60
Active, not recruiting
Phase 2
An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment (ISA-HC-NK)
2024-514527-42-00Karolinska Institutet, Karolinska Institutet62